Navigation Links
Strengthening fragile immune memories to fight chronic infections
Date:8/18/2011

After recovering from the flu or another acute infection, your immune system is ready to react quickly if you run into the same virus again. White blood cells called memory T cells develop during the infection and help the immune system remember the virus and attack it if it comes back.

But chronic infections such as those caused by viruses like HIV and hepatitis C are different. If the immune system can't clear the infection out of the body fast enough, the memory T cells that initially developed against the virus upon first encounter are lost. This poses a challenge for vaccine development.

Researchers at the Emory Vaccine Center have identified the conditions that make memory T cells slip away during persistent infections. They have also shown that a molecule called 2B4 on memory cells causes them to slow down during chronic infections. The results are published online this week in the journal Immunity.

The results have implications for vaccine design. The authors emphasize the importance of having vaccines that encourage the immune system to quickly control a potentially chronic infection or prevent it from gaining a foothold a task that some experimental vaccines against HIV's cousin SIV have accomplished.

"In a chronic infection, the memory T cells become so tightly regulated that they eventually are ineffective," says first author Erin West, an Emory graduate student in immunology and molecular pathogenesis. "This is why it's so important to have that initial strength at the beginning."

West and most of the co-authors are in the laboratory of Rafi Ahmed, PhD, director of the Emory Vaccine Center and a Georgia Research Alliance Eminent Scholar. Researchers from Harvard Medical School also contributed to the study, including W. Nicholas Haining and Cox Terhorst.

West and her colleagues studied mice infected by a meningitis virus which establishes a chronic infection. A weaker form of the virus can be cleared from the body in a couple weeks. They tracked nave T cells as well as memory T cells' responses to infections that varied in dose and persistence.

A molecule called 2B4 appears on memory T cells that are activated during chronic infections and slows them down, the Emory team found. This level of regulation probably helps control the immune system and prevents it from developing dangerous over-inflammation, West says.

"Perhaps the body says 'I can't take care of this, so I will shut down,' before too much inflammation and damage occurs," she says.

Emory researchers have identified other molecules that produce "immune exhaustion" on T cells such as PD-1, but 2B4 is different because it seems to specifically regulate memory T cells. If memory T cells are engineered to lack 2B4, they are better able to persist during a chronic infection, although it's not clear whether the cells are then more effective at fighting the infection, West says. Blocking 2B4 might be a way to enhance immune responses against chronic infections, but more information is needed about how it works, she says.

The researchers also found that memory T cells need more "help," in the form of signals from other T cells, in the setting of chronic infection. This is a reversal of the situation in acute infections, where memory T cells are quicker to respond and need less help, she says.

In the paper, the Emory team cites a HIV vaccine tested in Thailand that was shown to have some ability to block initial infection, and an experimental hybrid vaccine against SIV designed by scientists in Oregon that has shown similar effects. They suggest that their results could be used to tune future vaccine design efforts and take advantage of these successes.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Strengthening routine flu vaccination and health programs may improve pandemic vaccinations
2. Bone-Strengthening Drug Guards Against Spread of Breast Cancer
3. New clinical trial to examine medication to treat social withdrawal in Fragile X and autism
4. Fragile X researcher honored by March of Dimes
5. Study shows promise for new drug to treat Fragile X
6. U-M researchers discover way to block neurodegeneration in an adult form of Fragile X syndrome
7. Parents report a widely prescribed antibiotic is effective for fragile X treatment
8. UT Southwestern researchers uncover Fragile X syndrome genes role in shaping brain
9. Brain Develops Differently in Fragile X Syndrome
10. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
11. Penn researchers describe key molecule that keeps immune cell development on track
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology: